A Phase III Trial to Evaluate the Efficacy and Safety of ARVN001 (Triamcinolone Acetonide Suprachoroidal Injectable Suspension) in Patients with Macular Edema Secondary to Non-Infectious Uveitis
Latest Information Update: 30 Jul 2024
At a glance
- Drugs Triamcinolone (Primary)
- Indications Retinal oedema
- Focus Registrational; Therapeutic Use
- Sponsors Arctic Vision
- 29 Jul 2024 Results presented in the Clearside Biomedical Media Release.
- 04 Oct 2023 Status changed from recruiting to active, no longer recruiting, according to a Clearside Biomedical media release.
- 04 Oct 2023 According to a Clearside Biomedical media release, company announced that it has completed enrollment.